Literature DB >> 34926036

Duration of Dual Antiplatelet Therapy After Stent Implantation, Still an Enigma: A Systematic Review of Randomized Clinical Trials.

Muhammad Bin Aslam Zahid1,2,3, Marrium S Memon3, Mamatha Tappiti3, Vignarth Shantha Kumar4, Armaan M Nazir3, Bhavya Koganti3, Kunal Gupta3, Jihan A Mostafa5.   

Abstract

Dual antiplatelet therapy (DAPT) is used in patients after drug-eluting stent (DES) implantation to prevent stent thrombosis and ischemic events. The ideal duration of DAPT in patients after DES implantation is a topic of debate among clinicians. In the past, many research studies were published related to an optimal duration of DAPT after DES implantation. In common practice, DAPT should be continued for one year or more after percutaneous coronary intervention (PCI) followed by DES implantation. The duration of DAPT is significant as long-term DAPT has beneficial effects but is associated with side effects like bleeding. On the other hand, short-term DAPT has a lower risk of bleeding, but it increases the rate of stent thrombosis or ischemic events. Our aim in this systematic review is to solve the dispute regarding the duration of DAPT after DES implantation. So, we tried to find the efficacy and safety of short-term (six months) DAPT by compiling data from randomized control trials (RCTs).  We conducted this systematic review following the guidelines defined in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. We searched for our data from multiple databases like PubMed, Web of Science, ScienceDirect, and Google Scholar. We reviewed 10964 studies and then applied inclusion/exclusion criteria and PRISMA guidelines. Finally, we were left with only 21 studies regarding the optimal duration of DAPT after DES implantation. Our systematic review will help determine the non-inferiority of short-term (six months) DAPT to long-term (12 months) DAPT. Furthermore, we also noticed with short-term (six months) DAPT, there was decreased incidence of bleeding as compared to DAPT for long-term. But more studies were required to establish the safety and effectiveness of short-term (six months) DAPT compared to long-term (12 months) DAPT in patients after DES implantation.
Copyright © 2021, Aslam Zahid et al.

Entities:  

Keywords:  : acute coronary syndrome; acute myocardial infraction; drug eluting stent; dual anti-platelet therapy; primary percutaneous coronary intervention (pci); stent graft thrombosis

Year:  2021        PMID: 34926036      PMCID: PMC8671065          DOI: 10.7759/cureus.19549

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  18 in total

1.  2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors:  Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983

2.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.

Authors:  Robert W Yeh; Dean J Kereiakes; Philippe Gabriel Steg; Stephan Windecker; Michael J Rinaldi; Anthony H Gershlick; Donald E Cutlip; David J Cohen; Jean-Francois Tanguay; Alice Jacobs; Stephen D Wiviott; Joseph M Massaro; Adrian C Iancu; Laura Mauri
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

3.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983

4.  Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.

Authors:  Francesco Costa; David Van Klaveren; Fausto Feres; Stefan James; Lorenz Räber; Thomas Pilgrim; Myeong-Ki Hong; Hyo-Soo Kim; Antonio Colombo; Philippe Gabriel Steg; Deepak L Bhatt; Gregg W Stone; Stephan Windecker; Ewout W Steyerberg; Marco Valgimigli
Journal:  J Am Coll Cardiol       Date:  2019-02-26       Impact factor: 24.094

5.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.

Authors:  Stefanie Schulz-Schüpke; Robert A Byrne; Jurrien M Ten Berg; Franz-Josef Neumann; Yaling Han; Tom Adriaenssens; Ralph Tölg; Melchior Seyfarth; Michael Maeng; Bernhard Zrenner; Claudius Jacobshagen; Harald Mudra; Eberhard von Hodenberg; Jochen Wöhrle; Dominick J Angiolillo; Barbara von Merzljak; Nonglag Rifatov; Sebastian Kufner; Tanja Morath; Antonia Feuchtenberger; Tareq Ibrahim; Paul W A Janssen; Christian Valina; Yi Li; Walter Desmet; Mohamed Abdel-Wahab; Klaus Tiroch; Christian Hengstenberg; Isabell Bernlochner; Marcus Fischer; Heribert Schunkert; Karl-Ludwig Laugwitz; Albert Schömig; Julinda Mehilli; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-01-23       Impact factor: 29.983

6.  Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.

Authors:  Masato Nakamura; Raisuke Iijima; Junya Ako; Toshiro Shinke; Hisayuki Okada; Yoshiaki Ito; Kenji Ando; Hitoshi Anzai; Hiroyuki Tanaka; Yasunori Ueda; Shin Takiuchi; Yasunori Nishida; Hiroshi Ohira; Katsuhiro Kawaguchi; Makoto Kadotani; Hiroyuki Niinuma; Kazuto Omiya; Takashi Morita; Kan Zen; Yoshinori Yasaka; Kenji Inoue; Sugao Ishiwata; Masahiko Ochiai; Toshimitsu Hamasaki; Hiroyoshi Yokoi
Journal:  JACC Cardiovasc Interv       Date:  2017-06-26       Impact factor: 11.195

7.  6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).

Authors:  Romain Didier; Marie Claude Morice; Paul Barragan; Arif A L Noryani; Hussam A Noor; Talib Majwal; Thomas Hovasse; Philippe Castellant; Michel Schneeberger; Luc Maillard; Erwan Bressolette; Jaroslaw Wojcik; Nicolas Delarche; Didier Blanchard; Bernard Jouve; Olivier Ormezzano; Franck Paganelli; Gilles Levy; Joël Sainsous; Didier Carrie; Alain Furber; Jacques Berlan; Olivier Darremont; Hervé Le Breton; Anne Lyuycx-Bore; Antoine Gommeaux; Claude Cassat; Alain Kermarrec; Pierre Cazaux; Philippe Druelles; Raphael Dauphin; Jean Armengaud; Patrick Dupouy; Didier Champagnac; Patrick Ohlmann; Hakim Ben Amer; Robert G Kiss; Irme Ungi; Martine Gilard
Journal:  JACC Cardiovasc Interv       Date:  2017-06-26       Impact factor: 11.195

8.  6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.

Authors:  Joo-Yong Hahn; Young Bin Song; Ju-Hyeon Oh; Deok-Kyu Cho; Jin Bae Lee; Joon-Hyung Doh; Sang-Hyun Kim; Jin-Ok Jeong; Jang-Ho Bae; Byung-Ok Kim; Jang Hyun Cho; Il-Woo Suh; Doo-Il Kim; Hoon-Ki Park; Jong-Seon Park; Woong Gil Choi; Wang Soo Lee; Jihoon Kim; Ki Hong Choi; Taek Kyu Park; Joo Myung Lee; Jeong Hoon Yang; Jin-Ho Choi; Seung-Hyuk Choi; Hyeon-Cheol Gwon
Journal:  Lancet       Date:  2018-03-12       Impact factor: 79.321

9.  Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.

Authors:  James B Hermiller; Mitchell W Krucoff; Dean J Kereiakes; Stephan Windecker; P Gabriel Steg; Robert W Yeh; David J Cohen; Donald E Cutlip; Joseph M Massaro; Wen-Hua Hsieh; Laura Mauri
Journal:  JACC Cardiovasc Interv       Date:  2016-01-25       Impact factor: 11.195

10.  Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.

Authors:  Elvin Kedhi; Enrico Fabris; Martin van der Ent; Pawel Buszman; Clemens von Birgelen; Vincent Roolvink; Alexander Zurakowski; Carl E Schotborgh; Jan C A Hoorntje; Christian Hasbø Eek; Stéphane Cook; Marco Togni; Martijn Meuwissen; Niels van Royen; Ria van Vliet; Hans Wedel; Ronak Delewi; Felix Zijlstra
Journal:  BMJ       Date:  2018-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.